A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 25, 2025

Primary Completion Date

January 25, 2031

Study Completion Date

January 25, 2031

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

Pozelimab

Administered per the protocol

DRUG

Cemdisiran

Administered per the protocol

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY